Literature DB >> 25736687

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Jemima Escamilla1, Shiruyeh Schokrpur1, Connie Liu1, Saul J Priceman2, Diana Moughon1, Ziyue Jiang3, Frederic Pouliot4, Clara Magyar5, James L Sung1, Jingying Xu1, Gang Deng6, Brian L West7, Gideon Bollag7, Yves Fradet4, Louis Lacombe4, Michael E Jung6, Jiaoti Huang5, Lily Wu8.   

Abstract

Growing evidence suggests that tumor-associated macrophages (TAM) promote cancer progression and therapeutic resistance by enhancing angiogenesis, matrix-remodeling, and immunosuppression. In this study, prostate cancer under androgen blockade therapy (ABT) was investigated, demonstrating that TAMs contribute to prostate cancer disease recurrence through paracrine signaling processes. ABT induced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other cytokines that recruit and modulate macrophages, causing a significant increase in TAM infiltration. Inhibitors of CSF1 signaling through its receptor, CSF1R, were tested in combination with ABT, demonstrating that blockade of TAM influx in this setting disrupts tumor promotion and sustains a more durable therapeutic response compared with ABT alone. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25736687      PMCID: PMC4359956          DOI: 10.1158/0008-5472.CAN-14-0992

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

Review 1.  Tumor escape mechanisms in prostate cancer.

Authors:  Ashley M Miller; Pavel Pisa
Journal:  Cancer Immunol Immunother       Date:  2005-12-16       Impact factor: 6.968

2.  The changing landscape in the treatment of metastatic castration-resistant prostate cancer.

Authors:  Joelle El-Amm; Jeanny B Aragon-Ching
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168

3.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Authors:  Hongbing Chen; Yin Sun; Chengyu Wu; Clara E Magyar; Xinmin Li; Liang Cheng; Jorge L Yao; Steven Shen; Adeboye O Osunkoya; Chaozhao Liang; Jiaoti Huang
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

4.  An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation.

Authors:  Kelli P A MacDonald; James S Palmer; Stephen Cronau; Elke Seppanen; Stuart Olver; Neil C Raffelt; Rachel Kuns; Allison R Pettit; Andrew Clouston; Brandon Wainwright; Dan Branstetter; Jeffrey Smith; Raymond J Paxton; Douglas Pat Cerretti; Lynn Bonham; Geoffrey R Hill; David A Hume
Journal:  Blood       Date:  2010-08-03       Impact factor: 22.113

5.  Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.

Authors:  Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

6.  Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.

Authors:  Hisamitsu Ide; David B Seligson; Sanaz Memarzadeh; Li Xin; Steve Horvath; Purnima Dubey; Maryann B Flick; Barry M Kacinski; Aarno Palotie; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

Review 7.  New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.

Authors:  Gerhardt Attard; Juliet Richards; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

Review 8.  Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?

Authors:  Chen Lü; Andrew K Williams; Venu Chalasani; Carlos H Martínez; Joseph Chin
Journal:  Expert Opin Biol Ther       Date:  2010-11-17       Impact factor: 4.388

9.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

Review 10.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

View more
  73 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.

Authors:  Souhil Lebdai; Mathieu Gigoux; Ricardo Alvim; Alexander Somma; Karan Nagar; Abdel Rahmene Azzouzi; Olivier Cussenot; Taha Merghoub; Jedd D Wolchok; Avigdor Scherz; Kwanghee Kim; Jonathan Coleman
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

3.  Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.

Authors:  Wei Guan; Junhui Hu; Lu Yang; Ping Tan; Zhuang Tang; Brian L West; Gideon Bollag; Hua Xu; Lily Wu
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

4.  Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression.

Authors:  Camila R Consiglio; Olga Udartseva; Kimberly D Ramsey; Chioma Bush; Sandra O Gollnick
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

5.  Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.

Authors:  Diana L Moughon; Huanhuan He; Shiruyeh Schokrpur; Ziyue Karen Jiang; Madeeha Yaqoob; John David; Crystal Lin; M Luisa Iruela-Arispe; Oliver Dorigo; Lily Wu
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

Review 6.  The Promise of Targeting Macrophages in Cancer Therapy.

Authors:  J Martin Brown; Lawrence Recht; Samuel Strober
Journal:  Clin Cancer Res       Date:  2017-03-24       Impact factor: 12.531

Review 7.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 8.  Development and translation of novel therapeutics targeting tumor-associated macrophages.

Authors:  David Kosoff; Joshua M Lang
Journal:  Urol Oncol       Date:  2018-11-17       Impact factor: 3.498

Review 9.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

10.  CSF1R-dependent myeloid cells are required for NK‑mediated control of metastasis.

Authors:  Michal Beffinger; Paulino Tallón de Lara; Sònia Tugues; Marijne Vermeer; Yannick Montagnolo; Isabel Ohs; Virginia Cecconi; Giulia Lucchiari; Aron Gagliardi; Nikola Misljencevic; James Sutton; Roman Spörri; Burkhard Becher; Anurag Gupta; Maries van den Broek
Journal:  JCI Insight       Date:  2018-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.